Buy AHK-Cu Peptide Online | Copper Tripeptide-3 | Ala-His-Lys Copper | ≥99% Purity | CoA | SourceTides

Buy AHK-Cu Peptide Online from SourceTides.
AHK-Cu (L-Alanyl-L-Histidyl-L-Lysine Copper(II); INCI: Copper Tripeptide-3) is a synthetic copper-binding tripeptide with a single structural difference from GHK-Cu — alanine replaces glycine at the N-terminus.

That single amino acid substitution produces a compound with notably different biological targeting compared to its parent: where GHK-Cu acts broadly across skin, lung, and systemic tissue biology, AHK-Cu demonstrates concentrated activity on dermal papilla cells and hair follicles.

AHK-Cu was derived from albumin hydrolysate and is considered an endogenous-like peptide.
At picomolar concentrations — as low as 10⁻¹² M — it stimulates ex-vivo human hair follicle elongation, drives dermal papilla cell (DPC) proliferation, upregulates VEGF (angiogenesis), inhibits TGF-β1 (anti-fibrotic, counters DHT effects), and shifts the apoptotic balance toward cell survival via the Bcl-2/Bax pathway.

Research suggests AHK-Cu may stimulate Type I collagen production by up to 300%.
Caspase-3 fragmentation is reduced by 42.7% and PARP fragmentation by 77.5% in DPCs — key markers of the anti-apoptotic protection that distinguishes AHK-Cu as a hair follicle preservation compound rather than simply a growth stimulator.

Every SourceTides vial is lyophilised, tested at ≥99% HPLC purity with copper content confirmed, and ships with a full lot-specific Certificate of Analysis.
For in-vitro laboratory and topical research use only. Not for human consumption.

AHK-Cu Peptide — Technical Specifications

What Is AHK-Cu?

AHK-Cu (Ala-His-Lys-Cu) and GHK-Cu (Gly-His-Lys-Cu) differ by exactly one atom group: a methyl group on the alanine α-carbon that glycine lacks.
That structural difference — worth 14 daltons on the mass spectrum — redirects the compound’s biological activity toward a more targeted profile, concentrating its effects on dermal papilla cells, hair follicles, and scalp fibroblast biology.

GHK-Cu is the broad-spectrum regenerative compound: it modulates 4,000+ human genes, repairs multiple tissue types, and has been used in systemic wound healing, COPD lung biology, and full-body ageing research.
AHK-Cu is the precision tool: its DPC selectivity makes it the more appropriate compound when hair follicle biology, scalp angiogenesis, or DHT-related follicle miniaturisation is the specific research question.

AHK-Cu was derived from albumin hydrolysate and is considered an endogenous-like peptide — it has been isolated from human blood samples, suggesting the body naturally produces and circulates small quantities.
This endogenous character contributes to its high tolerability profile in published research and its absence from controlled substance lists in all surveyed jurisdictions.

The picomolar active concentration is one of the most striking aspects of AHK-Cu’s pharmacology.
Ex-vivo human hair follicle elongation has been documented at 10⁻¹² M (1 picomolar) — a concentration orders of magnitude lower than most synthetic peptide actives.
This ultra-high potency suggests receptor-mediated activity at DPCs rather than bulk substrate delivery, and has significant implications for research design (very low compound quantities can produce measurable biological signals).
When you buy AHK-Cu Peptide from SourceTides, you receive ≥99% HPLC-pure Ala-His-Lys-Cu²⁺ with copper content confirmed and MS identity verified.

AHK-Cu vs GHK-Cu: The One-Amino-Acid Difference That Matters

The Gly→Ala substitution at position 1 does more than change one letter in the sequence.
Glycine is the smallest amino acid — it has a hydrogen atom as its side chain, giving it rotational freedom in all directions.
Alanine adds a methyl group, introducing steric bulk and modifying the N-terminus geometry that interacts with target cells.

The consequence in published research is a shift toward dermal papilla cell selectivity.
GHK-Cu shows broad regenerative activity across fibroblasts, keratinocytes, lung tissue, liver cells, and neuronal cells.
AHK-Cu shows concentrated activity in DPCs and follicular tissue, with particularly potent effects on the VEGF and TGF-β1 pathways that govern follicle cycling and vascularisation.

Neither compound is superior in an absolute sense — they are complementary tools.
GHK-Cu is the choice when systemic regeneration, gene expression resetting, or multi-tissue research is the goal.
AHK-Cu is the choice when the research question is specifically about hair follicle biology, DPC survival, scalp angiogenesis, or DHT-mediated follicle miniaturisation.

How AHK-Cu Works — Five Interconnected Mechanisms

Mechanism 1 — Copper-Enzyme Activation

Like GHK-Cu, AHK-Cu chelates copper(II) and delivers it to copper-dependent enzymes in a controlled, non-toxic form.
The primary targets are lysyl oxidase (LOX) — required for collagen and elastin crosslinking — and Cu/Zn-superoxide dismutase (SOD1) — the cytoplasmic antioxidant enzyme that neutralises superoxide radicals.

Lysyl oxidase activation is the biochemical basis of AHK-Cu’s collagen-stimulating activity.
Without functional LOX, newly synthesised collagen fibrils cannot be crosslinked into mechanically stable fibre bundles — they are synthesised but never organised into load-bearing matrix.
AHK-Cu’s copper delivery activates LOX in both dermal fibroblasts and follicle-associated fibroblasts simultaneously.

SOD1 activation contributes to AHK-Cu’s antioxidant and anti-apoptotic profile in DPCs.
Superoxide generated in follicles during metabolic activity and environmental stress is neutralised more efficiently when SOD1 has adequate copper cofactor.
This enzymatic antioxidant protection complements the anti-apoptotic Bcl-2/Bax mechanism (see below).

Mechanism 2 — VEGF Upregulation and Scalp Angiogenesis

AHK-Cu stimulates dermal fibroblasts to produce VEGF (Vascular Endothelial Growth Factor) — the primary driver of new blood vessel formation (angiogenesis).
Hair follicles are among the most metabolically active structures in the skin.
They require a dense capillary network delivering oxygen, glucose, and growth factors to support the rapid cell division of the anagen (active growth) phase.

VEGF upregulation drives endothelial cell proliferation and capillary sprouting around follicle structures — directly improving the nutrient and oxygen supply to DPCs.
This vascular mechanism is particularly important in the follicle miniaturisation model: DHT-induced follicle miniaturisation is associated with reduced perifollicular vascularisation, and improving blood supply helps maintain follicle size and cycling capacity.

The AHK-Cu VEGF pathway also activates endothelial cells in parallel with fibroblasts.
Activated endothelial cells contribute to elastin and collagen production alongside fibroblasts, creating a coordinated vascular and structural regeneration response in the scalp dermis.

Mechanism 3 — TGF-β1 Inhibition: Countering DHT-Driven Follicle Miniaturisation

TGF-β1 (Transforming Growth Factor Beta-1) is the primary pro-fibrotic and pro-miniaturisation cytokine in androgenetic alopecia.
DHT (dihydrotestosterone) upregulates TGF-β1 production in DPCs, and elevated TGF-β1 drives follicle miniaturisation through two mechanisms: it promotes the shift from anagen (growth) to catagen (regression) phase, and it induces fibrosis around the follicle that physically restricts its diameter.

AHK-Cu inhibits TGF-β1 secretion by dermal fibroblasts in published assays.
By reducing TGF-β1 levels in the follicle microenvironment, AHK-Cu counteracts the primary downstream mediator of DHT-induced miniaturisation — without directly blocking androgen receptors or altering hormone levels.
This makes it a non-hormonal research tool for studying the TGF-β1 arm of androgenetic alopecia.

The TGF-β1 inhibition also has a direct anti-fibrotic benefit in wound healing contexts.
Excess TGF-β1 drives myofibroblast differentiation and excessive collagen deposition — the mechanism underlying hypertrophic scarring.
AHK-Cu’s TGF-β1 suppression therefore contributes to anti-fibrotic ECM remodelling alongside its hair biology effects.

Mechanism 4 — Bcl-2/Bax Apoptotic Balance Shift: DPC Survival

AHK-Cu’s most precisely quantified biological effect is its shift in the apoptotic balance of dermal papilla cells.
Published data reports: Bcl-2 (anti-apoptotic) upregulated; Bax (pro-apoptotic) downregulated; caspase-3 (apoptosis execution protease) reduced 42.7%; PARP fragmentation (apoptosis execution marker) reduced 77.5%.

These four apoptosis markers collectively confirm that DPCs treated with AHK-Cu are substantially protected from programmed cell death.
DPCs in actively miniaturising follicles show increased apoptosis rates — a primary mechanism by which the follicle regresses and shrinks.
By suppressing this apoptotic drive, AHK-Cu maintains DPC number and therefore sustains the follicle’s growth-regulatory capacity.

The Bcl-2/Bax pathway is also the primary target of conventional anti-apoptotic strategies in cell biology research.
Having a copper-peptide compound with well-characterised effects on this pathway — active at picomolar concentrations — provides a uniquely potent and clean research tool for studying follicle apoptosis biology without the confounders associated with genetic or small-molecule Bcl-2 modulators.

Mechanism 5 — ECM Remodelling and Collagen Synthesis (up to 300%)

AHK-Cu stimulates fibroblast production of Type I collagen by up to 300% in research assays — substantially higher than the ~2× increase documented for GHK-Cu at equivalent concentrations in fibroblasts.
This superior collagen stimulation appears to reflect AHK-Cu’s concentrated signalling through fibroblast-specific pathways rather than broadly distributing its activity across many tissue types.

Beyond collagen quantification, AHK-Cu modulates the extracellular matrix more comprehensively: it drives elastin synthesis alongside collagen, regulates MMP (matrix metalloproteinase) and TIMP (tissue inhibitor of metalloproteinases) balance for controlled matrix remodelling, and inhibits the TGF-β1-driven excess collagen deposition that produces fibrotic scar tissue.

The net ECM effect is organised matrix synthesis rather than excess deposition.
This parallels GHK-Cu’s anti-fibrotic wound healing biology but is expressed more strongly in the dermal fibroblast and follicle microenvironment context.
For researchers studying scalp dermis remodelling, post-procedure recovery, or follicle structural maintenance, this targeted ECM activity makes AHK-Cu the better research tool.

AHK-Cu Research Evidence

What Is AHK-Cu Used for in Research?

Formulating with AHK-Cu: Research and Development Guidelines

AHK-Cu Quality Control at SourceTides

Every batch of AHK-Cu Peptide passes these tests before release.
The MS identity verification — confirming the +14 Da mass shift vs GHK-Cu — is the critical checkpoint distinguishing AHK-Cu from GHK-Cu.

AHK-Cu Regulatory Status

Peer-Reviewed References

Frequently Researched Alongside AHK-Cu

These compounds are most commonly studied alongside AHK-Cu in hair biology, scalp, collagen, and skin regeneration research:

• GHK-Cu Cosmetic Peptide — The natural SAR comparison partner: one amino acid different; broad-spectrum vs DPC-targeted activity; studying AHK-Cu and GHK-Cu side-by-side is the canonical copper peptide SAR experiment revealing what the Gly→Ala substitution contributes
• GHK-Cu 50 mg Injectable — For extended in-vivo comparison studies running AHK-Cu vs GHK-Cu head-to-head in wound healing and scalp biology animal models requiring single-lot consistency
• BPC-157 — VEGFR2/NO/FAK angiogenesis and tissue repair; studied alongside AHK-Cu in scalp vascularisation research combining VEGF (AHK-Cu) and VEGFR2 (BPC-157) angiogenic pathways
• BPC-157 Capsules — Oral BPC-157 format; studied with AHK-Cu in systemic tissue repair and skin healing panels
• TB-500 (Thymosin Beta-4) — Actin cytoskeleton repair; keratinocyte and fibroblast migration; studied with AHK-Cu in wound closure models combining cell migration (TB-500) and collagen synthesis and DPC survival (AHK-Cu)
• Epithalon 10 mg — Khavinson telomere biology; studied with AHK-Cu in anti-ageing hair and skin research combining cellular longevity (Epithalon) with targeted follicle and ECM support (AHK-Cu)
• Melanotan-1 10 mg — MC1R agonist; DNA repair (NER); studied alongside AHK-Cu in skin research panels combining UV-DNA repair and photoprotection (Melanotan-1) with collagen synthesis and antioxidant defence (AHK-Cu)
• Ipamorelin 10 mg — Selective GH secretagogue; IGF-1 axis drives collagen synthesis; studied with AHK-Cu in skin regeneration panels combining GH-IGF-1 anabolic support and direct copper-mediated collagen activation
• Sermorelin 10 mg — GHRH agonist; GH/IGF-1; studied with AHK-Cu in hair biology protocols combining GH axis support (anagen phase regulation) and direct DPC activation (AHK-Cu)

Frequently Asked Questions